Coronary CT Angiogram: Longevity-Medicine Target Ranges for Women

What a Coronary CT Angiogram Actually Measures

A CCTA uses iodinated contrast and a high-speed CT scanner to produce three-dimensional images of the coronary arteries. Unlike a calcium score (CAC) alone, it shows you the full plaque burden: calcified plaques, soft (non-calcified) plaques, and mixed plaques. That distinction matters because soft plaques are more prone to rupture and are invisible on a standard CAC scan.

The CAD-RADS Reporting System

Results are standardized using the CAD-RADS 2.0 classification, developed jointly by the Society of Cardiovascular Computed Tomography, the American College of Radiology, and the American College of Cardiology:

• CAD-RADS 0: No plaque, no stenosis. The longevity target.
• CAD-RADS 1: Minimal plaque, <25% stenosis. Low near-term risk; lifestyle focus.
• CAD-RADS 2: Mild stenosis 25-49%. Medical therapy consideration.
• CAD-RADS 3: Moderate stenosis 50-69%. Functional testing usually recommended.
• CAD-RADS 4A/4B: Severe stenosis 70-99% or left main >50%. Urgent cardiology referral.
• CAD-RADS 5: Total occlusion.

For longevity medicine, CAD-RADS 0 with zero plaque burden is the explicit goal, not merely "no obstructive disease." A 30% stenosis that causes no symptoms today still represents biological age debt.

What Plaque Morphology Tells You

Plaque type predicts event risk independently of stenosis degree. A 2020 meta-analysis of 5,000 patients in JACC Cardiovascular Imaging found that the presence of low-attenuation plaque (a marker of lipid-rich, vulnerable plaque) was associated with a nearly four-fold increase in major adverse cardiac events compared with calcified plaque alone. Women in that dataset had a higher proportion of non-obstructive but high-risk plaque morphology, a finding that has been replicated in the WISE study.

Why Standard Risk Calculators Underestimate Women's Cardiac Risk

This is where most clinical conversations fail women. The Pooled Cohort Equations, used to estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk, were derived from cohorts in which women were underrepresented and female-specific risk factors were not included as inputs.

Risk Factors the Pooled Cohort Equations Miss in Women

The following conditions raise a woman's cardiovascular risk substantially but do not appear in standard risk calculators:

• Premature menopause (before age 40): Associated with a 1.5-fold increase in coronary heart disease risk compared with natural menopause at age 50-51.
• PCOS: Women with polycystic ovary syndrome have a two-fold higher prevalence of subclinical atherosclerosis on imaging compared with matched controls, independent of BMI.
• Hypertensive disorders of pregnancy (preeclampsia, gestational hypertension): A history of preeclampsia roughly doubles lifetime risk of ischemic heart disease, as stated in ACOG Practice Bulletin 222.
• Gestational diabetes: Approximately 50% of women with gestational diabetes develop type 2 diabetes within 10 years, accelerating vascular aging.
• Autoimmune disease: Lupus, rheumatoid arthritis, and antiphospholipid syndrome dramatically raise vascular inflammation and plaque risk.
• Premature ovarian insufficiency (POI): Loss of estrogen before age 40 removes the cardioprotective effect of estrogen at a time when peers still have it.

The WomanRx clinical framework groups these into three tiers of female-specific cardiovascular risk modifiers:

Tier 1 (major, equivalent to traditional risk factors): Premature menopause, POI, preeclampsia history, PCOS with metabolic syndrome.

Tier 2 (moderate, warrants imaging consideration): Gestational diabetes, recurrent pregnancy loss, autoimmune disease, early surgical menopause.

Tier 3 (additive, track longitudinally): Perimenopausal vasomotor symptom burden, elevated inflammatory markers at any life stage, female-pattern visceral adiposity.

If you fall into Tier 1, a CCTA (not just a CAC) is reasonable to discuss with your clinician even if your Pooled Cohort Equation score looks reassuring.

Longevity-Medicine Target Ranges: The Optimal vs. The "Normal"

There is a meaningful difference between what most labs report as "within normal limits" and what longevity medicine considers optimal. A CCTA that shows mild non-calcified plaque at age 45 is not a normal finding for a 45-year-old's biological age. It is early disease.

The Longevity Target: Zero Plaque

Peter Libby's group at Brigham and Women's Hospital has articulated the concept of plaque regression as a therapeutic endpoint, not merely stabilization. For preventive cardiology and longevity medicine, the goal is:

1. CAC score of 0 (or trend toward 0 if previously elevated)
2. No soft or mixed plaque on CCTA
3. No high-risk plaque features (low-attenuation plaque, positive remodeling, napkin-ring sign, spotty calcification)

In practice, the PROMISE trial demonstrated that CCTA-guided care led to a 37% reduction in major adverse cardiac events at 2 years compared with functional testing, driven largely by earlier initiation of preventive therapies in people with non-obstructive plaque.

When "Normal" Is Not Optimal

A CAD-RADS 1 result, minimal plaque with <25% stenosis, is often communicated to patients as "nothing significant." In longevity medicine terms, it is a signal that atherosclerosis has begun. The MESA study showed that any detectable coronary plaque, even non-obstructive, was associated with a significantly higher 10-year event rate than a CAC of zero.

For women specifically, a 2022 analysis from the SCOT-HEART trial found that non-obstructive coronary artery disease detected by CCTA carried a greater proportional increase in 5-year fatal or non-fatal myocardial infarction risk in women than in men. Women in that cohort with non-obstructive CAD had a five-year MI rate of 2.0% compared with 0.5% in women with no plaque.

How Hormones Change What You See on CCTA

Reproductive Years

Estrogen maintains arterial elasticity, supports favorable lipoprotein profiles (higher HDL, lower LDL), and suppresses vascular smooth muscle cell proliferation. Premenopausal women without female-specific risk factors have substantially lower plaque burden than age-matched men. A CCTA in an otherwise healthy 38-year-old woman would typically be expected to show CAD-RADS 0.

However, even in reproductive years, women with PCOS show higher rates of coronary plaque. A 2019 study in Fertility and Sterility found subclinical coronary atherosclerosis in PCOS women at a mean age of 32, a finding that argues for earlier CCTA consideration in this group.

Perimenopause: The Critical Window

The perimenopausal transition, typically spanning ages 45-55 but starting earlier in some women, is when vascular risk accelerates. Estrogen levels fluctuate and then decline. LDL cholesterol rises, HDL may fall, and inflammatory markers increase. The Study of Women's Health Across the Nation (SWAN) documented a measurable increase in carotid intima-media thickness and coronary artery calcification that tracked with the menopausal transition, independent of chronological age.

This is why a CCTA or at minimum a CAC scan in the late perimenopause (around age 48-52 for most women) gives you a meaningful baseline before the full impact of estrogen loss accumulates.

Postmenopause

After the final menstrual period, the protective effect of endogenous estrogen is gone. Postmenopausal women catch up to men in cardiovascular event rates within 10 years. The Women's Health Initiative showed that women who initiated hormone therapy more than 10 years after menopause had higher coronary event rates than placebo, establishing the "timing hypothesis." Women who initiated within 10 years (or before age 60) did not show that increase.

A CCTA performed at or around menopause can inform the hormone therapy timing decision. Women with no detectable plaque and low vascular age may have more to gain from early hormone therapy initiation than women who already have established soft plaque, where the risk-benefit calculation shifts.

Surgical Menopause and POI

If your ovaries were removed before natural menopause, or if you have POI, your vascular clock runs fast. A Mayo Clinic cohort study followed women who had bilateral oophorectomy before age 46 and found a significantly higher rate of cardiovascular mortality compared with women with intact ovaries. In this population, CCTA at age 40-45 is a reasonable consideration, not a longevity luxury.

What High-Risk Plaque Features Mean (and What to Do)

Not all plaque is equal. Modern CCTA software can characterize plaque composition with considerable precision. If your report mentions any of the following, ask your clinician directly what it means for your treatment plan.

High-Risk Plaque Features on CCTA

• Low-attenuation plaque (LAP): Lipid-rich core, most prone to rupture. Present in roughly 17% of patients with non-obstructive CAD.
• Positive remodeling: The artery expands outward to accommodate plaque, hiding stenosis on angiography but indicating active inflammation.
• Napkin-ring sign: A halo of low attenuation around a denser core. Rare but high specificity for vulnerable plaque.
• Spotty calcification: Small, heterogeneous calcific deposits, in contrast to the smooth, dense calcification of stable plaque.

If your CCTA shows any two of these features, the 2023 ACC/AHA Guideline on Chronic Coronary Disease recommends aggressive lipid lowering (LDL target <55 mg/dL with high-intensity statin or statin plus ezetimibe), regardless of stenosis degree.

Women-Specific Conditions That Warrant Earlier CCTA

PCOS

PCOS affects 8-13% of women of reproductive age and carries a metabolic phenotype that accelerates vascular aging. Insulin resistance, elevated androgens, and chronic low-grade inflammation all contribute. Given the evidence for subclinical atherosclerosis as early as the third decade, women with PCOS and metabolic syndrome may benefit from CCTA in their late 30s to early 40s rather than waiting for conventional screening age.

Endometriosis

Emerging evidence links endometriosis to elevated cardiovascular risk. A large Nurses' Health Study II analysis found a 62% higher risk of myocardial infarction and angina in women with confirmed endometriosis compared with those without. The mechanism is not fully established but may involve systemic inflammation and shared estrogenic pathways. Routine CCTA in endometriosis is not yet guideline-endorsed, but it is a reasonable consideration for women over 40 with additional risk factors.

Female-Pattern Metabolic Disease

Women accumulate visceral adipose tissue differently than men and often have normal BMI with metabolically unhealthy body composition. A 2021 analysis in JAMA Cardiology found that women with metabolically unhealthy obesity had significantly higher coronary plaque burden on CCTA than metabolically healthy women at the same BMI. Standard BMI cutoffs miss this group. CCTA provides direct arterial data that body composition metrics cannot.

Radiation, Contrast, and Practical Considerations for Women

Radiation Dose

Modern CCTA with prospective ECG-gating and iterative reconstruction delivers approximately 1-3 mSv. For reference, a chest X-ray delivers about 0.1 mSv, and annual background radiation in the US is roughly 3 mSv. Breast tissue does absorb some scatter radiation, but the absolute risk from a single CCTA is very low. The SCOT-HEART trialists estimated an excess cancer risk well below 0.1% from a single scan in their population.

For women in reproductive years who are considering a CCTA, discuss timing in your menstrual cycle (early follicular phase reduces breast sensitivity slightly) and ensure you are not pregnant before proceeding.

Contrast Considerations

Iodinated contrast is used for CCTA. Women with thyroid disease, particularly Hashimoto's thyroiditis and those on levothyroxine, should discuss contrast timing with their clinician, as iodine load can transiently affect thyroid function. Women with a known contrast allergy may require pre-medication.

Contrast is excreted in breast milk in very small quantities. The American College of Radiology manual on contrast media states that breastfeeding can continue without interruption after iodinated contrast administration, as less than 0.01% is absorbed from the infant's gut.

Pregnancy and CCTA

CCTA is not performed during pregnancy unless the clinical situation is life-threatening (for example, suspected coronary artery dissection in peripartum cardiomyopathy). Fetal radiation exposure from a CCTA is extremely low (estimated <0.1 mSv to the fetus), but the iodinated contrast and the non-urgent nature of longevity screening make pregnancy an absolute contraindication for elective CCTA. If you are trying to conceive, schedule your CCTA before starting fertility treatment or in the early follicular phase when pregnancy is unlikely.

Spontaneous coronary artery dissection (SCAD), a condition that accounts for up to 43% of myocardial infarctions in women under 50 and occurs disproportionately in the peripartum period, may be identified on CCTA. Women with a history of SCAD should have individualized counseling about repeat imaging and pregnancy planning.

How to Use Your CCTA Result in a Longevity Plan

If Your Result Is CAD-RADS 0 (No Plaque)

Your arteries look clean right now. This does not mean the work stops. In longevity medicine, a CAD-RADS 0 result at age 45-50 is a baseline, not a graduation. Repeat CAC or CCTA every 3-5 years, optimize your ApoB to below 60 mg/dL, maintain blood pressure below 120/80 mmHg, and protect your estrogen window with timely hormone therapy discussion if you are perimenopausal.

If Your Result Shows Non-Calcified Plaque

This is the finding that most often surprises women who assumed they were low-risk. Non-calcified plaque is early disease. Longevity medicine treats it aggressively: high-intensity statin, lifestyle modification, ApoB targeting, and glucose optimization. Discuss PCSK9 inhibitor therapy if LDL does not reach target. Reimage in 12-24 months to confirm plaque stability or regression.

If Your Result Shows High-Risk Plaque Features

Cardiology referral same week, not same month. The 2023 ACC/AHA chronic coronary disease guidelines are explicit: high-risk plaque features change the risk category and change the treatment intensity required, irrespective of the degree of luminal stenosis.

Who This Test Is Right For (and Who Should Wait)

Strong candidates:

• Women 45-65 with one or more female-specific risk factors (PCOS, premature menopause, preeclampsia history, POI, gestational diabetes)
• Women with an intermediate 10-year ASCVD risk (7.5-20%) where a result would change management
• Women with a family history of premature coronary artery disease in a first-degree relative under 65
• Women considering long-term hormone therapy who want to understand their vascular baseline
• Women in longevity programs aiming for biological age optimization

Not the right first test:

• Women under 40 with no female-specific risk factors (a CAC scan is a lower-cost, lower-complexity starting point)
• Women who are pregnant or actively trying to conceive
• Women with severe contrast allergy not amenable to pre-medication
• Women with eGFR <30 mL/min (contrast nephropathy risk)
• Women with established severe CAD already on guideline-directed therapy, where additional CCTA is unlikely to change management